home / stock / cyad / cyad news

CYAD News and Press, Celyad SA From 11/04/21

Stock Information
Company Name: Celyad SA
Stock Symbol: CYAD
Market: NASDAQ
Menu
CYAD CYAD Quote CYAD Short CYAD News CYAD Articles CYAD Message Board
Get CYAD Alerts

News, Short Squeeze, Breakout and More Instantly...
CYAD - Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 63rd ASH Annual Meeting and Exposition

MONT-SAINT-GUIBERT, Belgium, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that two abstrac...
CYAD - AMC, MFGP and CWH among per market gainers

Bed Bath & Beyond BBBY +53% after announcing plans to complete $1B buyback R. R. Donnelley & Sons RRD +40% on Q3 earnings. Glaukos GKOS +25% after updates on Medicare reimbursement rates iRhythm Technologies IRTC +24% and GLaukos surge after upd...

CYAD - Celyad Oncology Announces November 2021 Conference Schedule

MONT-SAINT-GUIBERT, Belgium, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company...

CYAD - Celyad Oncology to Present New Data on Allogeneic CAR T Therapy Program at the Society for Immunotherapy of Cancer Annual Meeting

MONT-SAINT-GUIBERT, Belgium, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that three abstr...
CYAD - Celyad Oncology Announces September 2021 Conferences Schedule

MONT-SAINT-GUIBERT, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Compan...

CYAD - Celyad Oncology EPS beats by $0.29

Celyad Oncology (NASDAQ:CYAD): 1H GAAP EPS of -€1.02/share. As of June 30, 2021, the company had cash and cash equivalents of €12M; Net cash used in operations stood at €12.2M compared to €14.6M in year ago quarter. Press Release For further details see: ...

CYAD - Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights

MONT-SAINT-GUIBERT, Belgium, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, to...
CYAD - Celyad Oncology to Announce First Half 2021 Financial Results and Host Conference Call

MONT-SAINT-GUIBERT, Belgium, July 29, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company...

CYAD - Celyad Oncology highlights new CAR T product, gives data update

Celyad Oncology (CYAD) highlights new preclinical allogeneic armored CAR T candidate developed from its shRNA platform.The submission of IND application for CYAD-203, a new first-in-class shRNA-based allogeneic, IL-18-armored CAR T candidate, expected in mid-2022.The company also provide...

CYAD - Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Research & Development Day

Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in relapsed/refractory multiple myeloma (r/r MM) showed dose dependent engraftment up to dose level three (300×10 6 cells per infusion) with no Graft-versus-Host disease reported to date Submission of IND application ...
Previous 10 Next 10